Authors: Croxtall, Jamie D.; Keating, Gillian M.

Source: Drugs, Volume 68, Number 10, 2008 , pp. 1465-1472(8)

Publisher: Adis International

Abstract:

▴ The fixed-dose combination of irbesartan/hydrochlorothiazide (HCTZ) is approved in the US for use as initial therapy in patients who are likely to need multiple agents to achieve their blood pressure (BP) goals.

▴ In a 12-week, randomized, double-blind, multicentre trial in 538 patients with moderate hypertension that was untreated or uncontrolled by monotherapy, the mean reduction from baseline in seated systolic BP (SeSBP) at week 8 (primary endpoint) was significantly greater with irbesartan/HCTZ than with either irbesartan or HCTZ as monotherapy.

▴ In addition, the proportion of patients with moderate hypertension achieving controlled BP (SeSBP <140 mmHg/seated diastolic BP [SeDBP] <90 mmHg) at 12 weeks was significantly greater with irbesartan/HCTZ combination therapy than with irbesartan or HCTZ monotherapy.

▴ In a 7-week, randomized, double-blind, multicentre trial in 697 patients with severe hypertension that was untreated or uncontrolled by monotherapy, a significantly greater proportion achieved a trough SeDBP of <90 mmHg following 5 weeks of combination therapy with irbesartan/HCTZ compared with irbesartan monotherapy (primary endpoint).

▴ Furthermore, the proportion of patients with severe hypertension achieving controlled BP of <140/90 mmHg was significantly greater at all timepoints of the trial compared with irbesartan monotherapy.

▴ Irbesartan/HCTZ combination therapy had a similar tolerability profile to irbesartan and HCTZ monotherapy. Most adverse events were of mild to moderate intensity.

Keywords: Adis Drug Profiles; Hypertension; Irbesartan/hydrochlorothiazide

Document Type: Research article

Affiliations: 1: Wolters Kluwer Health | Adis, Auckland, New Zealand, an editorial office of Wolters Kluwer Health, Conshohocken, Pennsylvania, USA

Publication date: 2008-01-01

Related content

• In this: publication
• By this: publisher
• In this Subject: Pharmacology ,  Therapeutics & Alternative Medicine
• By this author: Croxtall, Jamie D. ;  Keating, Gillian M.

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers